Pharmaceutical Executive

In today’s Pharmaceutical Executive Daily, GSK moves to strengthen its immunology pipeline with a $2 billion acquisition of RAPT Therapeutics, Atkins launches a new partnership to better understand consumer mindsets around GLP-1 use, and Shionogi agrees to acquire Pfizer’s remaining stake in ViiV Healthcare.

In today’s Pharmaceutical Executive Daily, Henlius enters a global exclusive licensing agreement with UMAb Biopharma for a potential best-in-class anti-IL-1RAP antibody, a new report highlights drugmakers raising list prices amid pricing agreements with the Trump administration, and Novartis urges governments to address mounting global trade policy challenges impacting the biopharmaceutical industry.

In today’s Pharmaceutical Executive Daily, Johnson & Johnson announces plans for a second $2 billion manufacturing facility in North Carolina, President Trump calls on Congress to enact a sweeping healthcare reform package, and new analysis highlights how frontline biopharma sales professionals are rethinking compensation and financial planning strategies.

In today’s Pharmaceutical Executive Daily we will focus on the 44th Annual J.P. Morgan Healthcare Conference, with Genmab outlining a disciplined strategy focused on sustained growth over the next decade, AbbVie highlighting continued pipeline advancements as it prepares for future revenue transitions, and Novavax detailing its shift toward a partnership-driven operating model.

In today’s Pharmaceutical Executive Daily we will focus on the 44th Annual J.P. Morgan Healthcare Conference, with Biogen outlining how a more focused company is emerging following years of transformation, Merck detailing its strategy to de-risk long-term funding and pipeline investment, and Eli Lilly reinforcing its confidence in sustaining GLP-1-driven growth.

In today’s Pharmaceutical Executive Daily, Johnson & Johnson reaches an agreement with the Trump administration while continuing its $55 billion U.S. investment plan, Bristol Myers Squibb outlines its long-term strategic focus at JPMorgan 2026, and Pfizer details its pivot from COVID-era products toward pipeline execution.

In today’s Pharmaceutical Executive Daily, the FDA moves to limit regulation of non-medical fitness wearables, industry leaders examine how humans and AI can jointly create value in pharma, and Eli Lilly enters a billion-dollar agreement to acquire Ventyx Biosciences.

In today’s Pharmaceutical Executive Daily, Eli Lilly and Nimbus Therapeutics announce a major licensing deal for oral obesity treatments, Hoth Therapeutics expands its intellectual property portfolio with new provisional patents, and Alnylam commits $250 million to expand manufacturing capabilities in Massachusetts.

In today’s Pharmaceutical Executive Daily, the Wegovy Pill becomes the first available oral GLP-1 for weight management, clears a new therapy to prevent motion-induced vomiting, and Sanofi enters a new antibody discovery collaboration targeting autoimmune disease.